Children's Medical Center Corporation

Cincinnati Children's Hospital Medical Center

Children's Hospital

Michael S O'Reilly

M Judah Folkman

Judah M Folkman

Yihai Cao

Kim Lee Sim

George S Abrams, Legal Representative

Steven Pirie-Shepherd

Jie Lin

Thomas Boehm

Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided.

Therapeutic antiangiogenic endostatin compositions

An inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 20 kDa and corresponds to a C-terminal fragment of collagen type XVIII, and methods of treating angiogenesis-related disease.

Nucleic acid molecules encoding endostatin protein and peptide fragments thereof

Nucleic acid sequence encoding kringle region fragment of plasminogen vectors comprising such nucleic acid, and methods of use of such nucleic acids, Ribonucleic and deoxyribonucleic acid sequence that encode for kringle region fragments are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogenesis-dependent cancer.

Nucleic acids encoding plasminogen fragments and methods of use

The present invention provides plasminogen fragments containing kringle region domains having anti-angiogenic activity and termed angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.

Angiostatin protein

Therapeutic antiangiogenic compositions and methods

Antibody to endostatin protein that is an inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 18 kDa as determined by non-reduced gel electrophoresis, and approximately 20 kDa as determined by reduced gel electrophoresis and corresponds to a C-terminal fragment of collagen type XVIII, and methods of detecting and treating angiogenesis-related disease therewith.

Antibodies to antiangiogenic compositions and methods

The present invention provides methods of inhibiting angiogenesis by increasing the concentration of kringle region fragments of plasminogen molecules in vivo. The methods of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.

Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen

The present invention provides anti-angiogenic compositions, and more particularly provides endostatin protein fragments. The compositions of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.

Endostatin protein and fragments thereof

Methods of inhibiting angiogenesis by administration of an isolated endostatin protein. Endostatin may be administered to individuals for treatment or repression of the growth of tumors, or administered to endothelial cells to inhibit their proliferation.

Methods of inhibiting angiogenesis with endostatin protein

The invention provides for methods of reducing or inhibiting angiogenesis, tumor growth and endothelial cell proliferation by the administration of compositions containing fragments, conformations, biological equivalent, or derivatives of antithrombin III. The invention also provides for pharmaceutical compositions comprising a fragment, conformation, biological equivalent, or derivative of antithrombin III and methods of identifying novel inhibitors of tumor growth, endothelial cell proliferation, and/or angiogenesis. The invention also relates to compositions and methods for altering angiogenesis in a mammal, as well as to methods of treatment for disorders associated with angiogenesis (e.g., cancer).

Compositions and methods for inhibiting angiogenesis

Methods for expressing endostatin protein

Nucleic acid sequences encoding kringle region fragments of plasminogen. Ribonucleic and deoxyribonucleic acid sequences that encode for kringle region fragments are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogenesis-dependent cancer.

Nucleic acids encoding plasminogen fragments

The present invention provides methods of inhibiting angiogenesis by increasing the concentration of endostatin protein or endostatin protein fragments in vivo. The methods of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.

Growing community of inventors

Winchester, MA, United States of America

Michael S O'Reilly